Browse evidence-based analysis of health-related claims and assertions
Taking chitosan supplements for 24 weeks may lead to a tiny weight loss compared to a placebo, but this difference is too small to be meaningful for health.
When belly fat decreases in people with HIV, liver fat also tends to decrease, showing a connection between these two types of fat.
A hormone treatment called tesamorelin lowers liver enzyme levels by 4 units more than a placebo in people with HIV after six months of treatment.
A hormone treatment called tesamorelin doesn't change the fat under the skin in people with HIV who have excess belly fat after six months of treatment.
A hormone treatment called tesamorelin temporarily raises blood sugar by 7 points more than a placebo in people with HIV after two weeks of treatment, but this effect goes away after six months.
A hormone treatment called tesamorelin lowers liver fat by 2.9% more than a placebo in people with HIV who have excess abdominal fat after six months of treatment.
A hormone treatment called tesamorelin decreases belly fat by 42 square centimeters more than a placebo in people with HIV who have excess abdominal fat after six months of treatment.
Measuring belly fat is more useful for understanding health risks in psoriasis patients than just checking body weight.
More visceral fat in psoriasis patients is linked to worse cholesterol profiles, increasing heart disease risk.
People with psoriasis or psoriatic arthritis have slightly more fat under the skin than healthy people with similar body weight, though this difference is not statistically significant.
People with psoriasis or psoriatic arthritis have a higher proportion of visceral fat within their abdominal cavity compared to healthy individuals with similar body weight.
Larger body size in psoriasis patients is strongly linked to worse disease control, as measured by standard disease activity scores.
People with psoriasis or psoriatic arthritis who have larger body sizes tend to report more difficulty with daily activities, as measured by standard health questionnaires.
More visceral fat in psoriasis patients is linked to lower levels of a protective hormone called adiponectin, which helps regulate metabolism.
More visceral fat in people with psoriasis is linked to higher insulin resistance, a key factor in diabetes risk, based on statistical analysis of the data.
People with psoriasis or psoriatic arthritis have a higher proportion of dangerous belly fat compared to safe fat under the skin, even when their overall weight is similar to healthy people.
People with psoriasis or psoriatic arthritis have about 6% more fat around their internal organs than people without these conditions, even when they have the same body weight.
After 6 months of oral semaglutide treatment, 32 people with type 2 diabetes had lower blood pressure, with an average drop of about 5%.
After 6 months of oral semaglutide treatment, 32 people with type 2 diabetes had lower liver enzyme levels, indicating improved liver health.
On average, 32 people with type 2 diabetes lost about 5% of their body weight after taking oral semaglutide for 6 months.
After 3 months of oral semaglutide treatment, 32 people with type 2 diabetes had a 16% lower score on a test for fatty liver disease.
After 3 months of taking oral semaglutide, 32 people with type 2 diabetes saw a better balance between muscle mass and belly fat, which improved further by 6 months but wasn't statistically significant.
Half of the 32 people with type 2 diabetes who took oral semaglutide for 6 months lost at least 5% of their body weight.
Taking oral semaglutide for 6 months helped lower blood sugar levels in 32 people with type 2 diabetes, reducing their HbA1c by about 9% on average.